HDAC-IN-35
HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC50 values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C17H13ClF3N3O3
- Molecular Weight:399.75
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
HDAC6 0.166 μM (IC50) |
HDAC8 1.99 μM (IC50) |
HDAC1 7.23 μM (IC50) |
VEGFR2 13.2 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
3.4 μM
Compound: 14
|
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34634618] |
| PC-3 | IC50 |
1.9 μM
Compound: 14
|
Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34634618] |
| SK-HEP1 | IC50 |
3.2 μM
Compound: 14
|
Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34634618] |
HDAC-IN-35 (Compound 14) (0-10 µM, 48 h) shows anticancer effects in different cancer cells[1].
HDAC-IN-35 (0-10 µM, 48 h) exhibits potent anti-angiogenic activity with a GI>50 (50% growth inhibition) value of 1.0 μM on human endothelial progenitor cells (EPCs) through a VEGFR-2-dependent pathway, without obvious systemic toxicity[1].
HDAC-IN-35 exhibits moderate VEGFR-2 inhibitory activities and displays the anticancer effects by inhibiting the enzymatic activity of HDAC[1].
HDAC-IN-35 (0-10 µM, 24 h) concentration-dependently impedes the capillary-like tube formation in human EPCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, PC-3, and SK-Hep-1
-
Concentration:0-10 µM
-
Incubation Time:48 h
-
Result:Showed anticancer effects with IC50 values of 3.4, 1.9 and 3.2 µM against A549, PC-3, and SK-Hep-1 cells.
-
Cell Line:A549, PC-3, and SK-Hep-1, and human EPCs
-
Concentration:0, 5, and 10 µM
-
Incubation Time:24 h
-
Result:Increased the amount of acetylated α-tubulin and histone H3 in a concentration-dependent manner in cancer cells. Induced mild inhibition of the phosphorylation of VEGFR-2 in human EPCs.
Chemical Information
-
Molecular Weight 399.75
-
Formel C17H13ClF3N3O3
-
SMILES
O=C(NO)/C=C/C1=CC=C(C=C1)NC(NC2=CC=C(C(C(F)(F)F)=C2)Cl)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
HDAC-IN-35 Related Classifications
HY-146539 Related Classifications
Powered by Bioz